Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: Induction of mineralization

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Prüfer, Jasmin ^a,b   Schuchardt, Mirjam ^a   Tölle, Markus ^a   Prüfer, Nicole ^a,c   Höhne, Matthias ^d   Zidek, Walter ^a   Van Der Giet, Markus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF POTSDAM   (Germany)

^d Novartis Germany GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; MERCAPTOPURINE; OSTEOCALCIN; TRANSCRIPTION FACTOR RUNX2; AZATHIOPRINE; CALCIUM; MINERAL; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RESPONSE; CAUSAL ATTRIBUTION; CELL COUNT; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSDIFFERENTIATION; CELL VIABILITY; CONCENTRATION RESPONSE; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; ANIMAL; AORTA; ARTERIOSCLEROSIS; CYTOLOGY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHENOTYPE; WISTAR RAT;

6-MERCAPTOPURINE; ANIMALS; AORTA; ARTERIOSCLEROSIS; AZATHIOPRINE; CALCIUM; DISEASE PROGRESSION; MINERALS; MUSCLE, SMOOTH, VASCULAR; PHENOTYPE; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES;

EID: 84904351555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101709     Document Type: Article

References (45)

1. Liefeldt L, Budde K (2010) Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk. Transpl Int 23: 1191-1204.
2. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, et al. (2003) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 18: 1731-1740. (Pubitemid 37098542)
3. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, et al. (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37: 1236-1241. (Pubitemid 34163575)
4. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, et al. (2002) Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 106: 2085-2090. (Pubitemid 35192814)
5. Sutton-Tyrrell K, Najjar SS, Boudreau RM, Venkitachalam L, Kupelian V, et al. (2005) Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 111: 3384-3390. (Pubitemid 40923391)
6. Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20: 1453-1464.
7. Shao JS, Cheng SL, Sadhu J, Towler DA (2010) Inflammation and the osteogenic regulation of vascular calcification: a review and perspective. Hypertension 55: 579-592.
8. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, et al. (2008) Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem 283: 15319-15327.
9. Mori K, Shioi A, Jono S, Nishizawa Y, Morii H (1999) Dexamethasone enhances In vitro vascular calcification by promoting osteoblastic differentiation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19: 2112-2118. (Pubitemid 29422242)
10. Bottomley MJ, Harden PN (2013) Update on the long-term complications of renal transplantation. Br Med Bull 106: 117-134.
11. Marechal C, Coche E, Goffin E, Dragean A, Schlieper G, et al. (2012) Progression of coronary artery calcification and thoracic aorta calcification in kidney transplant recipients. Am J Kidney Dis 59: 258-269.
12. Miller LW (2002) Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2: 807-818.
13. Arnol M, de Mattos AM, Chung JS, Prather JC, Mittalhenkle A, et al. (2008) Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation 86: 1844-1848.
14. Ross R, Glomset JA (1973) Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 180: 1332-1339.
15. Shioi A, Nishizawa Y, Jono S, Koyama H, Hosoi M, et al. (1995) Beta-glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 15: 2003-2009.
16. Schuchardt M, Tolle M, Prufer J, Prufer N, Huang T, et al. (2012) Uridine adenosine tetraphosphate activation of the purinergic receptor P2Y enhances in vitro vascular calcification. Kidney Int 81: 256-265.
17. Pires NM, Pols TW, de Vries MR, van Tiel CM, Bonta PI, et al. (2007) Activation of nuclear receptor Nur77 by 6-mercaptopurine protects against neointima formation. Circulation 115: 493-500. (Pubitemid 46184201)
18. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, et al. (2001) Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res 89: 1147-1154. (Pubitemid 34627872)
19. Xiao G, Jiang D, Thomas P, Benson MD, Guan K, et al. (2000) MAPK pathways activate and phosphorylate the osteoblast-specific transcription factor, Cbfa1. J Biol Chem 275: 4453-4459. (Pubitemid 30094689)
20. Karran P, Attard N (2008) Thiopurines in current medical practice: molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 8: 24-36.
21. Polifka JE, Friedman JM (2002) Teratogen update: azathioprine and 6-mercaptopurine. Teratology 65: 240-261. (Pubitemid 34492613)
22. Mardini HE, Arnold GL (2003) Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting. J Clin Gastroenterol 36: 390-395. (Pubitemid 36459132)
23. Deshpande AR, Abreu MT (2010) Optimizing therapy with 6-mercaptopurine and azathioprine: to measure or not to measure? Therap Adv Gastroenterol 3: 275-279.
24. Berry CE, Hare JM (2004) Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555: 589-606. (Pubitemid 38404582)
25. Halloran PF (2004) Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729.
26. Gearry RB, Barclay ML (2005) Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J Gastroenterol Hepatol 20: 1149-1157. (Pubitemid 41602556)
27. Haque S, Gordon C, Isenberg D, Rahman A, Lanyon P, et al. (2010) Risk factors for clinical coronary heart disease in systemic lupus erythematosus: the lupus and atherosclerosis evaluation of risk (LASER) study. J Rheumatol 37: 322-329.
28. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, et al. (2006) Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 54: 3790-3798. (Pubitemid 44955879)
29. van den Dorpel MA, Ghanem H, Rischen-Vos J, Man in't Veld AJ, Jansen H, et al. (1997) Conversion from cyclosporine A to azathioprine treatment improves LDL oxidation in kidney transplant recipients. Kidney Int 51: 1608-1612. (Pubitemid 27239919)
30. van den Dorpel MA, Veld AJ, Levi M, ten Cate JW, Weimar W (1999) Beneficial effects of conversion from cyclosporine to azathioprine on fibrinolysis in renal transplant recipients. Arterioscler Thromb Vasc Biol 19: 1555-1558. (Pubitemid 29263028)
31. Vanrenterghem YF, Claes K, Montagnino G, Fieuws S, Maes B, et al. (2008) Risk factors for cardiovascular events after successful renal transplantation. Transplantation 85: 209-216. (Pubitemid 351222383)
32. Symmons DP, Gabriel SE (2011) Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 7: 399-408.
33. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H (2011) Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378: 1419-1427.
34. Pols TW, Bonta PI, Pires NM, Otermin I, Vos M, et al. (2010) 6-mercaptopurine inhibits atherosclerosis in apolipoprotein e*3-leiden transgenic mice through atheroprotective actions on monocytes and macrophages. Arterioscler Thromb Vasc Biol 30: 1591-1597.
35. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938-942. (Pubitemid 34258697)
36. Wang AY, Wang M, Woo J, Lam CW, Li PK, et al. (2003) Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 14: 159-168. (Pubitemid 36032720)
37. Nguyen PT, Henrard S, Coche E, Goffin E, Devuyst O, et al. (2010) Coronary artery calcification: a strong predictor of cardiovascular events in renal transplant recipients. Nephrol Dial Transplant 25: 3773-3778.
38. DeLoach SS, Joffe MM, Mai X, Goral S, Rosas SE (2009) Aortic calcification predicts cardiovascular events and all-cause mortality in renal transplantation. Nephrol Dial Transplant 24: 1314-1319.
39. Roe P, Wolfe M, Joffe M, Rosas SE (2010) Inflammation, coronary artery calcification and cardiovascular events in incident renal transplant recipients. Atherosclerosis 212: 589-594.
40. Ducy P (2000) Cbfa1: a molecular switch in osteoblast biology. Dev Dyn 219: 461-471.
41. Taverne YJ, Bogers AJ, Duncker DJ, Merkus D (2013) Reactive oxygen species and the cardiovascular system. Oxid Med Cell Longev 2013: 862423.
42. Mody N, Parhami F, Sarafian TA, Demer LL (2001) Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 31: 509-519. (Pubitemid 32728438)
43. Liberman M, Bassi E, Martinatti MK, Lario FC, Wosniak J, Jr., et al. (2008) Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol 28: 463-470.
44. McGrath LT, Treacy R, McClean E, Brown JH (1997) Oxidative stress in cyclosporin and azathioprine treated renal transplant patients. Clin Chim Acta 264: 1-12. (Pubitemid 27336988)
45. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, et al. (2005) Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309: 1871-1874. (Pubitemid 41325100)